R&D | April 17, 2026
Revvity aims to accelerate breakthroughs in cancer research
Revvity is positioning its technologies as a connected engine for discovery
Revvity is positioning its technologies as a connected engine for discovery
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
One Health-based surveillance model to focus on bird sanctuaries and high-risk human populations
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
American College of Cardiology and Korean Society of Cardiology convene global experts to address rising cardiometabolic burden
The company reported net revenue of SEK 13.5 million for the full year 2025
The national platform brought together healthcare professionals, patient advocates, and stakeholders
This development signals a cleanup of Anlon’s borrowing profile and closure of legacy debt facilities
Discussions will focus on how private space stations can improve access, repeatability and commercial feasibility for advanced biotech experiments
Subscribe To Our Newsletter & Stay Updated
